Neil Woodford has added to a number of healthcare and biotech stocks in October in his £7.7bn Woodford Equity Income fund, despite continued weak performance from several stocks in the sector.
Healthcare stocks in the US have been suffering losses, following comments by Hilary Clinton about drug pricing, but Woodford (pictured) has continued to fervently defend the sector. Nonetheless, healthcare stocks have continued to struggle, with one of Woodford's holdings, BTG, being one of the main detractors from performance for the fund. Woodford defends healthcare amid ‘perverse' energy rally "BTG's half year results disappointed the market, primarily due to the slow adoption of Varithena, its treatment for varicose veins," the firm explained in its latest fund update. "This...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes